project id: TCGA-PAAD; case submitter id: TCGA-3A-A9IL; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.92; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 0.87; rna integrity number: 7.2; age at index: 39; days to birth: -14599; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Alive; year of birth: 1968; age at diagnosis: 14599; ajcc pathologic m: MX; ajcc pathologic stage: Stage I; ajcc pathologic t: T1; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 2741.0; icd 10 code: C25.1; last known disease status: not reported; morphology: 8246/3; primary diagnosis: Neuroendocrine carcinoma, NOS; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Body of pancreas; synchronous malignancy: No; tissue or organ of origin: Body of pancreas; tumor grade: Not Reported; year of diagnosis: 2007; treatment or therapy: no; alcohol history: No; is ffpe: false; weight: 30.0; composition: Not Reported; days to collection: 2505; days to sample procurement: 0; initial weight: 40.0; portion submitter id: TCGA-3A-A9IL-01A-11; percent lymphocyte infiltration: 40.0; percent monocyte infiltration: 20.0; percent necrosis: 0.0; percent neutrophil infiltration: 20.0; percent normal cells: 0.0; percent stromal cells: 20.0; percent tumor cells: 80.0; percent tumor nuclei: 80.0;